Sixty adults who have experienced acute coronary syndrome within the past 2-12 months from three states (Rhode Island, North Carolina, Minnesota) will be randomized to either (1) a coaching program for depressed mood and health behavior change (Behavioral Activation for Health and Depression; BA-HD), or (2) Enhanced Usual Care. This study will evaluate the feasibility and acceptability of study procedures and BA-HD, and establish protocol and measurement harmonization across three sites in preparation for a future multi-site efficacy trial.
Acute coronary syndrome (ACS) represents a significant public health burden, with the most recent estimates suggesting that over 1 million U.S. adults experience ACS per year. As individuals are acutely surviving ACS more often, the associated disease burden is increasing for both the healthcare system and the individual living post-ACS. Poor engagement in health behaviors post-ACS contributes to risk for recurrent ACS and mortality. Modifiable behavioral contributors include smoking, medication non-adherence, physical inactivity, and poor diet. Approximately 20% of post-ACS adults experience depression and depression is associated with worse engagement in critical health behaviors, which in turn, increases subsequent progression of cardiovascular disease. Treatment of depression alone improves, but does not eliminate, behavioral nonadherence. Behavioral Activation is a robust counseling treatment for depression with evidence of improvements in depressive symptoms across varied populations (including those with medication conditions). BA seeks to improve mood by increasing environmental reinforcement through collaborative, values-guided setting of "activation goals." The goal setting focus and structure of BA allows for seamless integration of health behavior targets and thus offers a potential framework to integrate depression and health behavior treatment. BA-HD may be a useful strategy to depression and multiple health behavior improvement post-ACS. However, this possibility requires further testing. The purpose of this study is to examine the feasibility and acceptability of a multisite pilot randomized controlled trial and test the initial potential effects of the intervention (BA-HD) on cardiovascular health and depressive symptoms relative to an Enhanced Usual Care control condition. Participants will be randomly assigned to either 12 weeks of tele-delivered BA-HD) or Enhanced Usual Care (i.e., one session of depression and heart disease education and provision of community mental health resources). Primary endpoints are feasibility of multisite recruitment procedures (e.g., recruitment rates at each site), feasibility of intervention and control procedures (e.g., percent of enrolled participants who complete the study), study retention (e.g., percent of participants who complete 3 month follow-up), and acceptability of intervention content and intervention delivery and control procedures. The investigators hypothesize that the intervention content and delivery will be 1) feasible and 2) acceptable. The investigators will also examine changes in cardiovascular health, depressive symptoms, medication adherence, affect, and quality of life.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
39
BA-HD includes 8 - 10 sessions delivered over 10-12 weeks. Sessions use behavioral activation techniques to connect patient core values with goal-setting targeting activities that improve mood, alongside personalized adjustments to cardiovascular health behaviors (i.e., tobacco cessation, medication adherence, physical activity, diet, and sleep). Educational materials and commercially available tools like activity trackers, pillboxes, and portion control aids will accompany the goal-setting process to facilitate behavior change.
Patients will receive depression and heart disease education, as well as a list of local mental health resources.
Hennepin Healthcare Research Institute
Minneapolis, Minnesota, United States
ECU Health
Greenville, North Carolina, United States
The Miriam Hospital
Providence, Rhode Island, United States
Recruitment feasibility
Number of participants randomized per month of recruitment
Time frame: Baseline
Study retention
Proportion of randomized participants who complete the 6 month assessment.
Time frame: Week 26
Treatment engagement
Dose of treatment received (i.e., session attendance)
Time frame: Week 13
Treatment Acceptability
Client Satisfaction Questionnaire-8; Scores range from 8-32 with higher scores indicating greater treatment satisfaction.
Time frame: Week 13
Cardiovascular Health
Life's Essential 8 (LE8) Score; The LE8 classifies cardiovascular (CV) health across eight CV risk metrics: diet, physical activity, nicotine exposure, sleep health, weight, blood pressure, total cholesterol, and hemoglobin A1C. Each individual LE8 component is assigned a value ranging from 0 to 100. A total score is created by averaging each component score. Higher total scores reflect better overall CV health.
Time frame: Week 13, Week 26
Depressive symptoms
Patient Health Questionnaire-9; Scores range from 0 to 27; higher scores indicate greater depressive symptoms.
Time frame: Week 13, Week 26
7 Day Moderate to Vigorous Physical Activity
Minutes spent in moderate to vigorous physical activity from 7 day Actigraph wear
Time frame: Week 13, Week 26
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Self-Reported Moderate to Vigorous Physical Activity
Minutes spent in moderate to vigorous physical activity over 7 days based on report from a 7 Day Physical Activity Recall interview
Time frame: Week 13, Week 26
Self-Reported Diet
Mediterranean Eating Pattern for Americans Questionnaire; Scores range from 0-16 with higher scores indicating greater consistency with mediterranean style diet
Time frame: Week 13, Week 26
7-day point prevalence abstinence from smoking
Self-report of no smoking, not even a puff, for 7 days; then Bio-chemically confirmed by carbon monoxide in a breath sample
Time frame: Week 13, Week 26
Sleep duration
Average hours of sleep per night over 7 nights assessed via 7 day Actigraph wear
Time frame: Week 13, Week 26
Self-reported sleep duration
Self-reported hours of sleep per night from the Pittsburgh Sleep Quality Index
Time frame: Week 13, Week 26
Body Mass Index
Body weight (kilograms)/ Height (meters squared)
Time frame: Week 13, Week 26
Blood pressure
Systolic and diastolic blood pressures (mmHg)
Time frame: Week 13, Week 26
Non-HDL cholesterol
mg/dL; measured via point of care testing
Time frame: Week 13, Week 26
Hemoglobin A1C
%; measured via point of care testing
Time frame: Week 13, Week 26
Medication adherence (cholesterol regimen)
DOSE-Nonadherence Extent of Nonadherence items will be used to assess self-reported medication adherence to cholesterol medication; scores range from 1-5.
Time frame: Week 13, Week 26
Medication adherence (blood pressure regimen)
DOSE-Nonadherence Extent of Nonadherence items will be used to assess self-reported medication adherence to blood pressure medication; scores range from 1-5
Time frame: Week 13, Week 26
Medication adherence (blood glucose regimen)
DOSE-Nonadherence Extent of Nonadherence items will be used to assess self-reported medication adherence to both oral and injectable medication (assessed separately) to manage blood glucose; scores range from 1-5
Time frame: Week 13, Week 26
Major Adverse Cardiac Events
Composite of hospitalization for unstable angina, urgent coronary revascularization, and non-fatal myocardial infarction determined via participant inquiry and confirmed through electronic medical record review
Time frame: Week 26
All-cause mortality
Electronic medical record review
Time frame: Week 26
Health Behavior Engagement Composite
A health behavior engagement composite score will be created that follows the LE8 scoring structure. LE8 component scores will be summed for physical activity, diet, combustible tobacco exposure, and sleep. Medication adherence will also be assigned a score ranging from 0 to 100 based on scaled DOSE-Nonadherence scores.
Time frame: Week 13, Week 26